Testing a changed cold virus, DNX-2401, in people whose high-grade glioma has come back
Original title: MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people, looking for the right dose and the side effects.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a lab-changed cold virus that is built to attack brain cancer cells.
Who this trial is for. This trial is for people with high-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary that has come back. It is testing DNX-2401, a virus made from the common cold virus and changed in the laboratory to target brain cancer cells and attack them.
Where it stands. There are no results yet. The trial is looking for the best dose and for the side effects the virus causes. Those answers are not in yet. The source does not report any results.
What this means, and what it doesn't
What it could mean: For now this tells you that a virus-based treatment is being tested in people whose high-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary has come back. If that sounds like your situation, you can ask your care team about it. They can tell you if it makes sense to look into.
What it doesn't mean: This does not mean DNX-2401 works. A trial is a test, not a proven treatment. Joining a trial is not a guarantee that it will help you. It is not a promise of a cure. It also does not mean you can join. The trial team decides who can take part.
Source: ClinicalTrials.gov, July 15, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.